# nebulabio.tech > Physics-driven, dataset-free generative AI for undruggable targets ## Posts - [NEBULA Wins i-Lab 2025 — France's Premier Deep-Tech Innovation Prize](https://nebulabio.tech/nebula-wins-i-lab-2025-frances-premier-deep-tech-innovation-prize/): NEBULA is proud to announce that it has been selected as a laureate of the i-Lab 2025 Concours d’Innovation, one of France’s most prestigious national awards recognizing the country’s most innovative and high-impact deep-tech projects. Operated under the France 2030 investment plan, the i-Lab prize distinguishes breakthrough ventures with strong potential to shape tomorrow’s industries. A Generative AI Platform for Next-Generation Drug Discovery NEBULA operates a patented generative AI platform, developed in-house, that reveals all conformations of therapeutic targets and accelerates the discovery of drug candidates with optimized profiles. The technology combines molecular biophysics-based modeling methods with artificial intelligence to […] - [Unlocking Undruggable Targets: Nebula Secures 225 000 GPU Hours on Jean Zay](https://nebulabio.tech/exciting-news-225-000-gpu-hours-awarded/): We’re excited to announce that Nebula Bio has been awarded 225 000 GPU hours on GENCI’s flagship AI Jean Zay supercomputer! This powerful compute boost will accelerate our AI-driven platform—so we can uncover disease targets once considered undruggable and fast-track the discovery of breakthrough therapies. Thank you to GENCI and our partners for making this possible. We look forward to sharing our progress and driving real impact in the undruggable targets world! - [Welcome Fabrice Balavoine, PhD, MBA, to NEBULA](https://nebulabio.tech/fabrice-balavoine-joins-nebula/): We are thrilled to announce that Fabrice Balavoine, PhD, MBA, has joined NEBULA. Fabrice brings over 20 years of leadership in innovative startups and deep expertise in drug discovery and pharmaceutical development. In his new role, he will drive NEBULA’s commercial growth by securing strategic partnerships with leading pharmaceutical companies. Education & Expertise Proven Track Record Throughout his career, Fabrice has: Previous Leadership Roles What Fabrice Will Do at NEBULA At NEBULA, Fabrice’s strategic vision and operational excellence will be instrumental in advancing our physics-based generative AI platform, enabling us to explore and map the complete 3D structural landscape of […] - [NEBULA’s Project Selected for Bourse French Tech Emergence (BFTE) with a Total Budget of 120,000 EUR](https://nebulabio.tech/nebulas-project-selected-for-bourse-french-tech-emergence-bfte-with-a-total-budget-of-120000-eur/): We are thrilled to share that NEBULA’s project has been selected for support under the Bourse French Tech Emergence (BFTE) program by Bpifrance, with a total project budget of 120,000 EUR. This competitive program backs deep-tech startups developing breakthrough technologies, helping them mature their research, validate market potential, and achieve key technical milestones. Why This Matters Deep-Tech Innovation:The BFTE program recognizes high-potential, disruptive projects—one of NEBULA’s core strengths. Acceleration & Growth:This support allows us to refine our business model, advance our R&D, and approach market entry with greater confidence. Strategic Support:We’ll tap into Bpifrance’s ecosystem and expertise to sharpen our […] - [NEBULA Takes Center Stage During Ministerial Visit with Clara Chappaz - Minister in charge of Artificial Intelligence and Digital Affairs](https://nebulabio.tech/nebula-takes-center-stage-during-ministerial-visit-with-clara-chappaz/): A Landmark Meeting at the Heart of AI Innovation NEBULA is thrilled to share highlights from a recent ministerial visit where we had the privilege of presenting our innovative AI-driven solutions for biomedical research to Clara Chappaz, the French Minister of Artificial Intelligence and Digital Affairs. This special event took place at the Loria laboratory and Inria center at the University of Lorraine, placing NEBULA in the spotlight among cutting-edge startups in the Grand Est region. NEBULA’s Spotlight Moment NEBULA has garnered attention for our computational biophysics approach to exploring biomolecules with therapeutic potential. By harnessing the power of artificial […] - [Understanding the 3D Structure of Drug Targets](https://nebulabio.tech/understanding-the-3d-structure-of-drug-targets/): Modern medicine often hinges on an invisible dance at the molecular level. Proteins twist, fold, and shift in our bodies, creating dynamic shapes that can be elusive to capture. When developing new treatments, it’s crucial to understand these movements—especially for a molecule known as a drug target. “If we only had a single snapshot of these molecules, it would be like trying to design a key by looking at a locked door without ever seeing the inside of the lock.” What Is a Drug Target? A drug target is typically a protein that a medicine will bind to in order […] - [NEBULA 2024: A Year of Milestones and a Promising Start to 2025](https://nebulabio.tech/nebula-2024-a-year-of-milestones-and-a-promising-start-to-2025/): Bright Beginnings for the New Year 2025 from NEBULA ✨ As we welcome 2025—a year brimming with potential and opportunity—the entire NEBULA team extends our warmest wishes to all who have joined us in revolutionizing drug target discovery through the transformative power of generative AI. We look forward to a year filled with groundbreaking collaborations, shared successes, and bold innovations in medicine and global health. Reflecting on NEBULA’s Founding and Rapid Growth Founded in November 2024, NEBULA is a young and dynamic venture with a clear mission: leveraging cutting-edge AI to advance precision medicine. Despite our brief history, we have […] - [NEBULA Awarded the Prestigious Prix Pépite 2024](https://nebulabio.tech/nebula-awarded-the-prestigious-prix-pepite-2024/): We are thrilled to announce that NEBULA has been selected as a laureate for the Prix Pépite 2024, a distinguished award recognizing innovation and entrepreneurship within the startup ecosystem. About Prix Pépite The Prix Pépite is an esteemed accolade awarded by the ministry to young entrepreneurs who demonstrate exceptional innovation and potential. This award not only honors our current achievements but also provides national and international exposure for NEBULA in the years following our creation. What This Means for NEBULA A Heartfelt Thank You We extend our deepest gratitude to our supporters, partners, and the jury for believing in NEBULA. […] - [NEBULA Takes the Stage at BioFIT Conference 2024 in Lille! 🌍](https://nebulabio.tech/nebula-takes-the-stage-at-biofit-conference-2024-in-lille-%f0%9f%8c%8d/): We are thrilled to share the highlights of NEBULA’s participation in the BioFIT Conference 2024 held in Lille on December 3-4. This event was a remarkable opportunity for us to engage with the brightest minds in the biotech and life sciences industries. 🚀 Pitching at the Start Up Slams One of the standout moments for NEBULA was our Start Up Slams pitch on stage. Presenting our vision and groundbreaking solutions to an audience of innovators, researchers, and industry leaders was both exhilarating and inspiring. Our pitch focused on: The positive feedback and enthusiasm we received reaffirm our commitment to driving […] - [Unveiling the Dynamic World of Drug Target Conformations: A New Frontier in Drug Discovery](https://nebulabio.tech/unveiling-the-dynamic-world-of-drug-target-conformations-a-new-frontier-in-drug-discovery/): In the intricate dance of molecular biology, proteins play a pivotal role as dynamic entities that constantly change shape to perform various biological functions. Understanding these protein conformations is crucial in the field of drug discovery, where the aim is to design therapeutics that effectively interact with target proteins. Despite advancements in computational biology and artificial intelligence (AI), capturing the full spectrum of protein dynamics remains a significant challenge. This article explores the importance of discovering drug target conformations and how it can transform pharmaceutical research. The Complexity of Protein Dynamics Proteins are not static structures; they are highly dynamic […] ## Pages - [Cookie Policy](https://nebulabio.tech/cookie-policy/): Last updated: 13 September 2025 What we use No advertising/marketing cookies are used. Your choices On your first visit, you can accept or refuse non-essential cookies. You can change your choices at any time: Cookie Settings Cookies list The list below is maintained automatically by our consent tool. Contact NEBULA — Email: nebula@nebulabio.tech See our Privacy Policy. - [Privacy Policy](https://nebulabio.tech/privacy-policy/): Last updated: 13 September 2025 Controller & contact NEBULAEmail: nebula@nebulabio.tech Personal data we process Purposes & legal bases Recipients Trusted service providers (hosting, security and—if enabled—analytics) processing data under our instructions. Transfers If data are transferred outside your region by our providers, we use safeguards required by law (e.g., EU Standard Contractual Clauses). Retention We keep data only as long as needed for the purposes above, then delete or anonymize them. When we cannot give fixed periods, we apply criteria such as legal retention duties and operational needs. Your rights You can request access, rectification, erasure, restriction, portability, and object […] ## Optional - [Agent (MCP protocol)](websites-agents.hostinger.com/nebulabio.tech/mcp) [comment]: # (Generated by Hostinger Tools Plugin)